

LAG3 & CTLA4 Research Grade Pavunalimab

Catalog No.	DHD30408A DHD30408B	Quantity:	100 µg 1.0 mg
Alternate Names:	Bispecific, XmAb-22841, Bavunalimab, CAS: 2329669-78-3		
Description:	Research Grade Pavunalimab is a humanized bispecific monoclonal antibody directed against human Lymphocyte activation gene 3 protein (LAG-3, CD223) and human Cytotoxic T-lymphocyte protein 4 (CTLA-4, CD152)		
UniProt ID (target):	P18627 & P16410		
Target:	Bispecific human LAG-3 (CD223) and CTLA-4 (CD152)		
Concentration:	1.0 mg/ml, lot specific		
Source:	XtenCHO		
Isotype:	Human half-IGG1-kappa/(scFv-heavy-kappa)-h-CH2-CH3		
Formulation:	Sterile-filtered 0.01 M PBS, pH 7.4		
Purity:	> 95% by SDS-PAGE		
Endotoxin Level:	≤ 0.01 EU/µg by LAL analysis		
Purification:	Protein A/G affinity chromatography		
INN:	Pavunalimab		
Applications:	Functional studies		
Storage & Stability:	Store at 2-8°C for up to 1 week, or in working aliquots at -20°C to -80°C for up to 1 year. Avoid freeze/thaw cycles.		

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

